Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.

Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.

Show other versions (1)

Many anticancer therapies, including ionizing radiation (IR), cause cytotoxicity through generation of DNA double-strand breaks (DSB). Delivery of therapeutic radionuclides to DNA DSB sites can amplify this DNA damage, for additional therapeutic gain. Herein, we report on two radiopharmaceuticals, r...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Cornelissen, B, Waller, A, Able, S, Vallis, K
Format:	Journal article
Sprog:	English
Udgivet:	American Association for Cancer Research 2013

Lignende værker

Molecular radiotherapy using cleavable radioimmunoconjugates that target eGFR and γH2AX
af: Cornelissen, B, et al.
Udgivet: (2013)

Can γH2AX be used to personalise cancer treatment?
af: Shah, K, et al.
Udgivet: (2013)

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical
af: Cornelissen, B, et al.
Udgivet: (2012)

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
af: Cornelissen, B, et al.
Udgivet: (2012)

γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies
af: Shah, K, et al.
Udgivet: (2015)

Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates.
af: Cornelissen, B, et al.
Udgivet: (2011)

Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR
af: Luke Yongkyu Kwon, et al.
Udgivet: (2024-05-01)

New radioimmunoconjugate -dota-h-r3. synthesis and radiolabeling
af: Denis R. Beckford Vera, et al.
Udgivet: (2007-01-01)

EP-2324: Non-invasive PET imaging of radiosensitive tumour regions using γH2AX-targeted immunoconjugate
af: Yaromina, A, et al.
Udgivet: (2018)

The Phosphorylated Form of the Histone H2AX (γH2AX) in the Brain from Embryonic Life to Old Age
af: Adalberto Merighi, et al.
Udgivet: (2021-11-01)

The kinetics of γ-H2AX during radiotherapy of head and neck cancer potentially allow for prediction of severe mucositis
af: Kazmierska Joanna, et al.
Udgivet: (2020-02-01)

Intracellular delivery of radioimmunoconjugates that target the cancer testis antigen, NY-ESO-1
af: Chu, H
Udgivet: (2013)

Generation of an alpaca‐derived nanobody recognizing γ‐H2AX
af: Malini Rajan, et al.
Udgivet: (2015-01-01)

Predictive effect of γH2AX expression on the radiosensitivity of glioma
af: Jun-wei WANG, et al.
Udgivet: (2014-03-01)

In vivo Analysis of H2AX Phosphorylation Induced by γ-Radiation
af: Seyed Mostafa Mir, et al.
Udgivet: (2017-03-01)

PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.
af: Knight, J, et al.
Udgivet: (2015)

On cleavability
af: Levine, S
Udgivet: (2012)

Accumulation of 111In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Co-administration of Targeting Ligand
af: Song, L, et al.
Udgivet: (2017)

PET imaging of DNA damage using 89Zr-labelled anti-γH2AX-TAT immunoconjugates
af: Knight, J, et al.
Udgivet: (2015)

Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation
af: Lourenço, J
Udgivet: (2024)

89Zr-anti-γH2AX-TAT allows early monitoring of response to gemcitabine and capecitabine therapy in pancreatic ductal adenocarcinoma
af: Knight, J, et al.
Udgivet: (2016)

Residual γH2AX foci as an indication of lethal DNA lesions
af: Banuelos C Adriana, et al.
Udgivet: (2010-01-01)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
af: Cornelissen, B, et al.
Udgivet: (2008)

Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.
af: Glatting, G, et al.
Udgivet: (2006)

Increased γ-H2A.X intensity in response to chronic medium-dose-rate γ-ray irradiation.
af: Takashi Sugihara, et al.
Udgivet: (2012-01-01)

Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery
af: Guanren Zhao, et al.
Udgivet: (2017-06-01)

DNA Damage Sensor γ-H2AX Is Increased in Preneoplastic Lesions of Hepatocellular Carcinoma
af: Yasunobu Matsuda, et al.
Udgivet: (2013-01-01)

A portable microfluidic fluorescence spectrometer device for γ-H2AX-based biological dosimetry
af: Pope, I, et al.
Udgivet: (2011)

Developable spaces and cleavability
af: F. CAMMAROTO, et al.
Udgivet: (1994-09-01)

EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.
af: Song, L, et al.
Udgivet: (2016)

Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma
af: Ashleigh Hull, et al.
Udgivet: (2022-09-01)

Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma
af: Raquel Benedetto, et al.
Udgivet: (2018-04-01)

ATM and SIRT6/SNF2H Mediate Transient H2AX Stabilization When DSBs Form by Blocking HUWE1 to Allow Efficient γH2AX Foci Formation
af: Yuko Atsumi, et al.
Udgivet: (2015-12-01)

Imaging DNA damage response (DDR) during oncogenesis
af: Cornelissen, B, et al.
Udgivet: (2013)

Targeting the tumour: Cell penetrating peptides for molecular imaging and radiotherapy
af: Kersemans, V, et al.
Udgivet: (2010)

Radiation exposure lymphocyte damage assessed by γ-H2AX level using flow cytometry
af: Zhuoqing Chen, et al.
Udgivet: (2024-02-01)

PARP1 exhibits enhanced association and catalytic efficiency with γH2A.X-nucleosome
af: Deepti Sharma, et al.
Udgivet: (2019-12-01)

Development of a high-throughput γ-H2AX assay based on imaging flow cytometry
af: Younghyun Lee, et al.
Udgivet: (2019-08-01)

Positioning of nucleosomes containing γ-H2AX precedes active DNA demethylation and transcription initiation
af: Stephanie Dobersch, et al.
Udgivet: (2021-02-01)

Cohesin protects genes against γH2AX Induced by DNA double-strand breaks.
af: Pierre Caron, et al.
Udgivet: (2012-01-01)